Literature DB >> 24206450

Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.

Robbert Crusio1, Sriharsha Rao, Nisarg Changawala, Vishesh Paul, Ceres Tiu, Joost van Ginkel, Edward Chapnick, Yizhak Kupfer.   

Abstract

INTRODUCTION: Infections with carbapenem-resistant Gram-negative bacteria (CRGNB) are increasing and are associated with a high mortality. Synergistic effects of combination therapy with a polymyxin, carbapenem, and rifampin have been observed in in vitro studies. Clinical data are limited to retrospective studies.
METHODS: We performed an observational cohort study of patients over 18 y of age who were treated with polymyxin B combination therapy.
RESULTS: One hundred and four patients were studied. The mean age was 77 y; 73% had recently received antibiotics, 67% had recently been hospitalized, and 47% lived in a nursing facility. The most common infections were pneumonia and urinary tract infection due to Acinetobacter baumannii (33%), Klebsiella pneumoniae (24%), and Pseudomonas aeruginosa (11%). Treatment regimens included polymyxin B with a carbapenem in 48%, with additional rifampin in 23%. Clinical success was achieved in 50% and reinfection occurred in 25%. Treatment-related acute renal failure occurred in 14.4%. No treatment-related hemodialysis was needed. All-cause hospital mortality was 47% and mortality after 6 months was 77%. No significant difference was found between treatment regimens. Age (odds ratio (OR) 10.4 per 10 y, p = 0.04), severity of acute illness (OR 2.2 per point, p < 0.001), and Charlson score (OR 1.12 per point, p = 0.04) were associated with hospital mortality. K. pneumoniae was associated with increased hospital survival compared to other CRGNB (p = 0.03).
CONCLUSION: CRGNB infections are associated with previous antibiotic and health care exposure. Mortality is related to age and the severity of chronic and acute illness.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24206450     DOI: 10.3109/00365548.2013.844350

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  13 in total

1.  In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.

Authors:  Xiuzhen Di; Rui Wang; Bin Liu; Xin Zhang; Wentao Ni; Jin Wang; Beibei Liang; Yun Cai; Youning Liu
Journal:  J Antibiot (Tokyo)       Date:  2015-03-25       Impact factor: 2.649

2.  Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.

Authors:  Sameer S Kadri; Samuel F Hohmann; E John Orav; Stephanie L Bonne; Matthew A Moffa; Joseph G Timpone; Jeffrey R Strich; Tara Palmore; Kenneth B Christopher; Christy Varughese; David C Hooper; Robert L Danner
Journal:  Clin Infect Dis       Date:  2014-09-22       Impact factor: 9.079

3.  Transferrin iron starvation therapy for lethal bacterial and fungal infections.

Authors:  Lin Lin; Paul Pantapalangkoor; Brandon Tan; Kevin W Bruhn; Tiffany Ho; Travis Nielsen; Eric P Skaar; Yaofang Zhang; Ruipeng Bai; Amy Wang; Terence M Doherty; Brad Spellberg
Journal:  J Infect Dis       Date:  2014-01-19       Impact factor: 5.226

Review 4.  Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis.

Authors:  Chienhsiu Huang; Ihung Chen; Tiju Tang
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

5.  Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-resistant Infections: A Systematic Review and Meta-analysis.

Authors:  Samir Samal; Shakti B Samir; Shantanu K Patra; Arun Rath; Abhilash Dash; Biswajit Nayak; Diganta Mohanty
Journal:  Indian J Crit Care Med       Date:  2021-02

6.  Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study.

Authors:  Yiying Cai; Hui Leck; Ray W Tan; Jocelyn Q Teo; Tze-Peng Lim; Winnie Lee; Maciej Piotr Chlebicki; Andrea L Kwa
Journal:  Antibiotics (Basel)       Date:  2020-07-27

7.  Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand.

Authors:  Thundon Ngamprasertchai; Adhiratha Boonyasiri; Lantharita Charoenpong; Sireethorn Nimitvilai; Narisorn Lorchirachoonkul; Luksame Wattanamongkonsil; Visanu Thamlikitkul
Journal:  Infect Drug Resist       Date:  2018-08-20       Impact factor: 4.003

8.  From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB).

Authors:  Yiying Cai; Nathalie Grace Chua; Tze-Peng Lim; Jocelyn Qi-Min Teo; Winnie Lee; Asok Kurup; Tse-Hsien Koh; Thuan-Tong Tan; Andrea L Kwa
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

Review 9.  Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.

Authors:  Suneel Kumar Garg; Omender Singh; Deven Juneja; Niraj Tyagi; Amandeep Singh Khurana; Amit Qamra; Salman Motlekar; Hanmant Barkate
Journal:  Crit Care Res Pract       Date:  2017-07-06

Review 10.  The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings.

Authors:  Frank Jones; Yanmin Hu; Anthony Coates
Journal:  Antibiotics (Basel)       Date:  2022-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.